P/E ratio for Repligen (RGEN)

P/E ratio history for Repligen from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Pfizer PFE	19.6	-85.56%	🇺🇸 USA
Thermo Fisher Scientific TMO	27.0	-80.18%	🇺🇸 USA
General Electric GE	35.3	-74.06%	🇺🇸 USA
Bristol-Myers Squibb BMY	17.5	-87.12%	🇺🇸 USA
Sangamo Therapeutics SGMO	-0.2709	-100.20%	🇺🇸 USA
Novavax NVAX	2.89	-97.87%	🇺🇸 USA
Neurocrine Biosciences NBIX	27.3	-79.91%	🇺🇸 USA
Bio-Techne TECH	106	-21.77%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	29.6	-78.22%	🇺🇸 USA
Charles River Laboratories CRL	-56.6	-141.62%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.